Nuvation Bio Inc. Deferred Costs, Current
Nuvation Bio Inc. (NUVB) had Deferred Costs, Current of $772.07 million as of 2021-12-31, per its 10-Q filed 2022-05-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2022-05-09
- 2021-12-31: Deferred Costs, Current $772.07M; Deferred Costs, Current as first filed $0.00.
- 2021-09-30: Deferred Costs, Current $0.00.
- 2021-06-30: Deferred Costs, Current $0.00.
- 2021-03-31: Deferred Costs, Current $0.00.
| Period end | Deferred Costs, Current | Deferred Costs, Current as first filed |
|---|---|---|
| 2021-12-31 | $772.07M 10-Q · filed 2022-05-09 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $2.92M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |